Spazgan, tablets 20 pcs

Spazgan is a combination drug, belongs to the group of aldehydic and antispasmodic agents. The drug consists of: non-narcotic analgesic sodium metamizole (analginum), myotropic antispasmodic agent pitophenone hydrochloride and choline-blocking agent fenpiperinia bromide.

Methamisole is a derivative of pyrosolone. It has analgesic, antipyretic, and mild anti-inflammatory effects.

Pitophenone, like papaverine, has a direct myotropic effect on the smooth muscles of internal organs and causes them to relax.

Phenpiveryinia has an additional relaxing effect on the smooth muscles due to its cholin-blocking action.

The combination of the three components of the drug leads to a mutual strengthening of their pharmacological action.

Indications

Pain of various origins
spasms of internal organs (renal colic, biliary colic)
postoperative pain. spasms of cerebral vessels.

Pharmacological effect

Spazgan is a combination drug that belongs to the group of aldehytic and antispasmodic drugs. The drug contains: the non-narcotic analgesic metamizole sodium (analgin), the myotropic antispasmodic drug pitofenone hydrochloride and the anticholinergic drug fenpiverinium bromide.

Metamizole is a derivative of pyrozolone. It has an analgesic, antipyretic, and weak anti-inflammatory effect.

Pitophenone, like papaverine, has a direct myotropic effect on the smooth muscles of internal organs and causes its relaxation.

Due to its anticholinergic effect, fenpiverinium has an additional relaxing effect on smooth muscles.

The combination of the three components of the drug leads to a mutual enhancement of their pharmacological action.

Special instructions

In patients suffering from bronchial asthma, taking the drug can provoke the development of an attack.

Active ingredient

Metamizole sodium, Pitophenone, Fenpiverinium bromide

Composition

Each tablet contains:

active substances:

metamizole sodium – 500 mg,

pitofenone hydrochloride – 5.0 mg,

fenpiverinium bromide – 0.1 mg;

excipients: lactose – 164,000 mg, magnesium stearate – 5,000 mg, colloidal silicon dioxide – 0,100 mg.

Pregnancy

The use of the drug in nursing mothers requires cessation of breastfeeding.

Contraindications

agranulocytosis
coronary heart disease
glaucoma
prostate adenoma
severe hepatic-renal failure
hypersensitivity to the components of the drug.

Side Effects

decrease in the number of leukocytes in the blood
drop in blood pressure
renal dysfunction
allergic reactions.

Interaction

The simultaneous use of Spazgan with other non-narcotic analgesics can lead to mutual enhancement of toxic effects.

Tricyclic antidepressants, oral contraceptives, and allopurinol disrupt the metabolism of metamizole in the liver and increase its toxicity.

Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effect of metamizole. Simultaneous use with cyclosporine reduces the level of the latter in the blood. Sedatives and tranquilizers enhance the analgesic effect of Spazgan.

If it is necessary to use these and other medications simultaneously, you should consult your doctor.

Overdose

Symptoms: vomiting, decreased blood pressure, drowsiness, confusion, nausea, vomiting, pain in the epigastric region, impaired liver and kidney function, convulsions.

Treatment: gastric lavage, administration of activated carbon, symptomatic therapy.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Wockhardt Ltd, India